Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: Male

Summary

Survival benefit and quality of life are two key elements that should be kept in mind in the treatment of metastatic breast cancer. In this regards, endocrine therapy (ET) is strongly recommended in hormone receptor (HR) positive patients unless there is visceral crisis even though there is no concrete evidence that it is better than chemotherapy in terms of survival.

HER2 positive breast cancer is a subtype of breast cancer that showed the greatest improvement in terms of survival during the last decade due to trastuzumab based therapy. Recently, taxane and HER2 directed doublet including trastuzumab and pertuzumab (THP) is considered as standard of therapy based upon randomized phase 3 clinical trial (CLEOTATRA).

HER2 positive breast cancer can be divided into HER2 enriched subgroup (HR-HER2+) and luminal B subgroup (HR+HER2+) in biologic viewpoint because they are distinctly different subgroups in gene expression analysis. Accordingly, we are currently treating biologically different subtypes in a same way, which is CTx and anti-HER2 combination therapy (THP).

Luminal HER2+ subgroup has actually been tested with endocrine therapy (ET) and anti-HER2 therapy showed better PFS than ET alone (TAnDEM trial and trial comparing lapatinib plus letrozole versus letrozole alone) [2],[3] confirming existence of cross talk between ER and HER2 pathways in clinical setting. However, the combination regimen between ET and anti-HER2 therapy is not widely used in current practice in ER+HER2+ MBC patients because PFS seemed to be relatively shorter compared with chemotherapy based combination with anti-HER2 therapy even though several guidelines recommend it to be used as an initial treatment unless there is visceral crisis as they recommended ET alone first in ER+HER2- MBC (NCCN 2018).

Recently, various CDK4/6 inhibitors including palbociclib, abemaciclib, and ribociclib were approved by FDA based on the clinical trial results demonstrating prolonged PFS over ET alone when it was combined with ET in ER+ advanced breast cancer [4]. In PALOMA 2 biomarker study, it was beneficial regardless of ER and Ki67 expression status.

Reflecting quite durable PFS prolongation (10 month in PALOMA2) shown in ER+ disease (luminal A and luminal B subtype except HR+HER2+ patients) with CDK4/6 inhibitor on top of ET, the hypothesis of this trial is whether CDK4/6 inhibitor could prolong survival in luminal HER2 breast cancer as it did in ER+HER2-patients. In preclinical study, palbociclib showed activity in not only ER+ cell lines but also HER2 positive cell lines [5]. Also, in phase Ib trial, a CDK4/6 inhibitor from Lilly, abemaciclib showed acceptable toxicity with endocrine therapy or trastuzumab with response rate of around 20%.

Hence, as of today, it could be justified and warranted to conduct a prospective trial of ribocicib+letrozole+trastuzumab in order to take a look at its efficacy and toxicity in HR+HER2 + advanced breast cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Letrozole; Trastuzumab

Criteria

Inclusion Criteria:

• Patients aged ≥19 years

• Women with advanced (loco-regionally recurrent or metastatic) breast cancer not amenable for curative therapy

• Histologically and/or cytologically confirmed estrogen receptor positive and/or progesterone receptor positive breast cancer

• HER2 positive breast cancer (IHC 3+ or IHC 2+ and FISH, SISH or CISH+)

• Postmenopausal patient defined as either one of the following.

• Prior bilateral ovariectomy

• Age ≥ 60 years old

• Age <60 years and amenorrhea over 12 months (without chemotherapy, tamoxifen, toremifene or ovarian inhibition), FSH and estradiol are in the postmenopausal range according to local normal range

• Patients who were not previously treated with systemic treatment for advanced / metastatic breast cancer

• ECOG performance status 0 or 1

• Measurable or evaluable lesion according to RECIST v1.1

• Normal organ function defined as

• ANC (absolute neutrophil count) ≥ 1.5 × 109/L

• Platelet ≥ 100 × 109/L

• Serum Hb ≥ 9.0 g/dL

• INR ≤1.5

• Serum creatinine ≤ 1.5 X ULN

• ALT & ALT < 2.5 X ULN (in the absence of liver metastasis) or ALT & ALT < 5 X ULN (with liver metastasis)

• Total serum bilirubin < 1.5 X ULN

• Left Ventricular Ejection Fraction (LVEF) within normal range

• Voluntary agreement on clinical trials

Exclusion Criteria:

• Patients who have previously received CDK4 / 6 inhibitors or who have received other systemic treatments for advanced / metastatic breast cancer (Previous neo-adjuvant of adjuvant trastuzumab or aromatase inhibitor is not allowed, unless

1. Disease free interval was more than 12 months from the last dose of adjuvant trastuzumab or

2. Adjuvant aromatase inhibitor was administered more than 2 years)

• Inflammatory breast cancer

• Central nervous system metastasis

• Active cardiac disease or a history of cardiac dysfunction including any of the following (Congestive heart failure within 6 months, history of myocardial infarction, unstable angina pectoris, or QTc prolongation on electrocardiogram)

• Gastrointestinal absorption disorders that interfere with drug absorption

• Patients who is currently receiving medications that can prolong QT intervals (QTc>450msec) on ECG or that can cause torsades de pointes

• Patients with severe visceral metastasis on enrolment who are not indicated with hormone treatment

• Serious surgical treatment within 14 days prior to study treatment

• Radiotherapy within 21 days prior to study treatment

• Serious medical comorbidities

• Concurrent malignancy or malignancy within 3 years of study participation, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.